Boston Scientific

Open: 54.7 Close: 54.1 Change: -0.6

Our AI found 11 flaws in Boston Scientific.

How much time have you spent trying to decide whether investing in Boston Scientific? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Boston Scientific are: …

Concept Map

Semantic Network

Stock Summary

Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat.

Today's Summary

Analysts maintain their “Buy’s “buy’ rating for Boston Scientific. CEO Mike Mahoney wants to make Boston Scientific a “compelling” and “fantastic place to be 10 years from now. Analysts say the company maintains a drug-free workplace.

Today's News

CEO Mike Mahoney wants to make Boston Scientific a “compelling” and “fantastic place to be 10 years from now. The company is making moves — in M&A, digital and more. Analysts maintain their “Buy” rating for Boston Scientific. The analysts view on Boston Scientific Investor Day. Boston Scientific Corp. has agreed to buy privately held medical technology company Relievant Medsystems Inc. in $850m cash deal. The company maintains a drug-free workplace. The incumbent will lead a category team of cross-functional partners in Supplier Quality and Supplier Engineering to achieve objectives and collaborate with divisional stakeholders. Boston Scientific Clonmel is hiring a Regulatory Affairs Specialist II. Boston Scientific expects to close the transaction in the first half of 2024, subject to satisfaction of customary closing conditions. As the only U.S. 1 ″We anticipate this novel, clinically-backed technology can support our category leadership strategy while expanding access to care. Boston Scientific is in the Health Care sector and Health Care Equipment & Supplies industry. Boston Scientific expects to close the transaction in the first half of 2024, subject to satisfaction of customary closing conditions. Boston Scientific expects to close the transaction in the firsthalf of 2024, subject to satisfaction of customary closing conditions. Boston Scientific Neuromodulation president Jim Cassidy said: “We anticipate this novel, clinically-backed technology can support our category leadership strategy” Boston Scientific is proud to be an equal opportunity and affirmative action employer. Boston Scientific maintains a drug-free workplace. Boston Scientific agreed to acquire Relievant Medsystems, a medical technology company that developed a system for chronic back pain. Boston Scientific ( NYSE:BSX – Get Free Report ) last announced its earnings results on Thursday, July 27th. Boston Scientific had a net margin of 6.81% and a return on equity. Boston Scientific has made an upfront cash payment of $850 million to take over Relievant Medsystems. The deal is the latest in a string of acquisitions by Boston Scientific to boost its portfolio of medical devices. Boston Scientific hiring Field Service Engineer - New England in Boston, Massachusetts, United States. Be among the first 25 applicants See who Boston Scientific has hired. Boston Scientific has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept ® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. Boston Scientific expects to close the transaction in the first half of 2024. Boston Scientific expects to close the transaction in the first half of 2024.

Stock Profile

"Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts."

Keywords

This document will help you to evaluate Boston Scientific without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Boston Scientific are: Boston, Scientific, company, technology, expect, close, transaction, and the most common words in the summary are: boston, scientific, job, stock, news, market, bsx, . One of the sentences in the summary was: CEO Mike Mahoney wants to make Boston Scientific a “compelling” and “fantastic place to be 10 years from now. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #boston #scientific #job #stock #news #market #bsx.